Literature DB >> 34120579

Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant.

Claude Kwe Yinda1, Julia R Port1, Trenton Bushmaker1, Robert J Fischer1, Jonathan E Schulz1, Myndi G Holbrook1, Carl Shaia2, Emmie de Wit1, Neeltje van Doremalen1, Vincent J Munster1.   

Abstract

The circulation of SARS-CoV-2 has resulted in the emergence of variants of concern (VOCs). It is currently unclear whether the previous infection with SARS-CoV-2 provides protection against reinfection with VOCs. Here, we show that low dose aerosol exposure to hCoV-19/human/USA/WA-CDC-WA1/2020 (WA1, lineage A), resulted in a productive mild infection. In contrast, a low dose of SARS-CoV-2 via fomites did not result in productive infection in the majority of exposed hamsters and these animals remained non-seroconverted. After recovery, hamsters were re-exposed to hCoV-19/South African/KRISP-K005325/2020 (VOC B.1.351) via an intranasal challenge. Seroconverted rechallenged animals did not lose weight and shed virus for three days. They had a little infectious virus and no pathology in the lungs. In contrast, shedding, weight loss and extensive pulmonary pathology caused by B.1.351 replication were observed in the non-seroconverted animals. The rechallenged seroconverted animals did not transmit the virus to naïve sentinels via direct contact transmission, in contrast to the non-seroconverted animals. Reinfection with B.1.351 triggered an anamnestic response that boosted not only neutralizing titres against lineage A, but also titres against B.1.351. Our results confirm that aerosol exposure is a more efficient infection route than fomite exposure. Furthermore, initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351 but prevents disease and onward transmission. These data suggest that previous SARS-CoV-2 exposure induces partial protective immunity. The reinfection generated a broadly neutralizing humoral response capable of effectively neutralizing B.1.351 while maintaining its ability to neutralize the virus to which the initial response was directed against.

Entities:  

Keywords:  B.1.351; SARS-CoV-2; Syrian hamster; aerosol; fomite; neutralization; reinfection

Mesh:

Substances:

Year:  2021        PMID: 34120579     DOI: 10.1080/22221751.2021.1943539

Source DB:  PubMed          Journal:  Emerg Microbes Infect        ISSN: 2222-1751            Impact factor:   7.163


  15 in total

1.  Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2.

Authors:  Julia Port; Claude Kwe Yinda; Victoria Avanzato; Jonathan Schulz; Myndi Holbrook; Neeltje van Doremalen; Carl Shaia; Robert Fischer; Vincent Munster
Journal:  Res Sq       Date:  2021-08-09

2.  Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo.

Authors:  Julia R Port; Claude Kwe Yinda; Victoria A Avanzato; Jonathan E Schulz; Myndi G Holbrook; Neeltje van Doremalen; Carl Shaia; Robert J Fischer; Vincent J Munster
Journal:  Nat Microbiol       Date:  2022-01-11       Impact factor: 30.964

3.  SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern.

Authors:  David W Hawman; Kimberly Meade-White; Jacob Archer; Shanna Leventhal; Drew Wilson; Carl Shaia; Samantha Randall; Amit P Khandhar; Tien-Ying Hsiang; Michael Gale; Peter Berglund; Deborah Heydenburg Fuller; Heinz Feldmann; Jesse H Erasmus
Journal:  bioRxiv       Date:  2021-12-13

Review 4.  Advances and gaps in SARS-CoV-2 infection models.

Authors:  César Muñoz-Fontela; Lina Widerspick; Randy A Albrecht; Martin Beer; Miles W Carroll; Emmie de Wit; Michael S Diamond; William E Dowling; Simon G P Funnell; Adolfo García-Sastre; Nora M Gerhards; Rineke de Jong; Vincent J Munster; Johan Neyts; Stanley Perlman; Douglas S Reed; Juergen A Richt; Ximena Riveros-Balta; Chad J Roy; Francisco J Salguero; Michael Schotsaert; Lauren M Schwartz; Robert A Seder; Joaquim Segalés; Seshadri S Vasan; Ana María Henao-Restrepo; Dan H Barouch
Journal:  PLoS Pathog       Date:  2022-01-13       Impact factor: 6.823

5.  The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters.

Authors:  Timothy Carroll; Douglas Fox; Neeltje van Doremalen; Erin Ball; Mary Kate Morris; Alicia Sotomayor-Gonzalez; Venice Servellita; Arjun Rustagi; Claude Kwe Yinda; Linda Fritts; Julia Rebecca Port; Zhong-Min Ma; Myndi Holbrook; Jonathan Schulz; Catherine A Blish; Carl Hanson; Charles Y Chiu; Vincent Munster; Sarah Stanley; Christopher J Miller
Journal:  bioRxiv       Date:  2021-08-25

6.  Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques.

Authors:  Vincent J Munster; Meaghan Flagg; Manmeet Singh; Claude Kwe Yinda; Brandi N Williamson; Friederike Feldmann; Lizzette Pérez-Pérez; Jonathan Schulz; Beniah Brumbaugh; Myndi G Holbrook; Danielle R Adney; Atsushi Okumura; Patrick W Hanley; Brian J Smith; Jamie Lovaglio; Sarah L Anzick; Craig Martens; Neeltje van Doremalen; Greg Saturday; Emmie de Wit
Journal:  Sci Adv       Date:  2021-10-22       Impact factor: 14.136

7.  The B.1.427/1.429 (epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters.

Authors:  Timothy Carroll; Douglas Fox; Neeltje van Doremalen; Erin Ball; Mary Kate Morris; Alicia Sotomayor-Gonzalez; Venice Servellita; Arjun Rustagi; Claude Kwe Yinda; Linda Fritts; Julia Rebecca Port; Zhong-Min Ma; Myndi G Holbrook; Jonathan Schulz; Catherine A Blish; Carl Hanson; Charles Y Chiu; Vincent Munster; Sarah Stanley; Christopher J Miller
Journal:  PLoS Pathog       Date:  2022-02-10       Impact factor: 6.823

8.  Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study.

Authors:  Giovanni Corrao; Matteo Franchi; Federico Rea; Danilo Cereda; Antonio Barone; Catia Rosanna Borriello; Petra Giulia Della Valle; Michele Ercolanoni; Ida Fortino; Jose Jara; Olivia Leoni; Francesco Mazziotta; Elisabetta Pierini; Giuseppe Preziosi; Marcello Tirani; Massimo Galli; Guido Bertolaso; Giovanni Pavesi; Francesco Bortolan
Journal:  BMC Med       Date:  2022-02-08       Impact factor: 8.775

9.  Increased aerosol transmission for B.1.1.7 (alpha variant) over lineage A variant of SARS-CoV-2.

Authors:  Julia R Port; Claude Kwe Yinda; Victoria A Avanzato; Jonathan E Schulz; Myndi G Holbrook; Neeltje van Doremalen; Carl Shaia; Robert J Fischer; Vincent J Munster
Journal:  bioRxiv       Date:  2021-07-26

10.  Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques.

Authors:  Vincent J Munster; Meaghan Flagg; Manmeet Singh; Brandi N Williamson; Friederike Feldmann; Lizzette Pérez-Pérez; Beniah Brumbaugh; Myndi G Holbrook; Danielle R Adney; Atsushi Okumura; Patrick W Hanley; Brian J Smith; Jamie Lovaglio; Sarah L Anzick; Craig Martens; Neeltje van Doremalen; Greg Saturday; Emmie de Wit
Journal:  bioRxiv       Date:  2021-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.